Flagship-Pioneered Ampersand Biomedicines Emerges with Novel Programmable Drug Platform

Flagship Pioneering arrives with a new technology platform.

On March 7, Ampersand Biomedicines, founded two years ago, made its public debut. Flagship provided $50 million in initial R&D funding, bringing this emerging biotech company into the public eye.

Image source: Ampersand Biomedicines official website

Currently, drug developers largely rely on differences in target expression levels to achieve a balance between safety and efficacy.Ampersand is dedicated to developing safer, better-tolerated, and more effective programmable drugs that act exclusively at the site of disease by designing and programming more efficient therapeutic agents. As a platform technology, it addresses a key challenge in drug development: precise targeting and reduction of off-target toxicity.

Flagship has been seeking solutions to this problem over the past two years. Now, Flagship is ready to unveil its work from the past two years and accelerate collaborative and clinical initiatives for the platform.

Regarding another ambitious platform company incubated by Flagship, several senior industry investors told VCBeat New Medicine that they are highly interested in its technology and strategic direction and will continue to monitor its progress.

Ampersand Biomedics was founded in 2020 at Flagship Labs.

Flagship has assembled the initial leadership team for the company. Like many other companies incubated by Flagship, Ampersand’s management team is largely drawn from Flagship’s own ranks. Flagship Partner Dr. Avak Kahvejian serves as Founding CEO, while Dr. Raffi Afeyan, nephew of Flagship founder Noubar Afeyan, leads the innovation and strategy division.

The name Ampersand hints at the two-component structure of its drug: the “locator” and the “driver.”“A locator” is a molecule with specific affinity for a particular site in the body. This component is linked to a small-molecule “driver,” which delivers the therapeutic effect. Common drug modalities—such as small molecules, proteins, and nucleic acids—can all serve as drivers. According to Kahvejian, this structure is conceptually similar to antibody–drug conjugates, but these elements extend beyond the scope of antibodies or cytotoxic agents. For example, the therapeutic moiety can include proteins, small molecules, or therapeutic oligonucleotides. “We are not limited to one format or modality,” says Kahvejian.

Over two quiet years, Ampersand Biomedicines has built its Address, Navigate, Design (AND)™ platform technology. This platform computationally analyzes RNA transcription data from across the human body, generated or acquired by the company. Through this analysis, Ampersand is constructing a new map of the human body. The AND technology continuously learns to identify rules for optimal locator targets, which in turn enhances its ability to design novel drugs.

Leveraging AND™ platform technology, Ampersand has developed the “AND-Body™ Therapy,” designed to create next-generation modular therapeutics that act precisely where needed in the body, without affecting other areas.. Kahvejian stated that this drug platform can be extended to “almost any disease.”. However, at present, this preclinical startup has not disclosed any disease areas of focus.

Ampersand has not yet disclosed specific details on how it plans to realize the aforementioned concepts. Kahvejian stated that the company is currently creating “prototypes” for drugs it intends to develop in the future, with animal trials now underway. The company’s next step is to seek partnerships; large pharmaceutical companies may be interested in leveraging Ampersand’s technology to identify their own molecular candidates, while others may wish to undertake the development of potential drug candidates generated by the startup’s platform.

For the new company established by Flagship, as one of the few investors in China capable of partnering with Flagship,CDH Investments, Liu DanThe PhD remarked, “Throughout our long-term collaboration, one of Flagship’s core investment theses has been ‘precision medicine,’ which involves designing and developing drugs through various disruptive and cutting-edge approaches. Ampersand is a prime example of this strategy, with its two core platforms being big data and computational modeling. The goal is to deliver precise therapeutics to specific targets to achieve precise efficacy and improve success rates. Many diseases manifest in specific organs, yet their mechanisms of action are systemic. Therefore, the selection of indications is critical—for instance, choosing local diseases caused by autoimmune or metabolic disorders—because non-selective treatment can disrupt systemic homeostasis and cause side effects. Previously, drug developers also struggled extensively with controlling drug exposure across different tissues.”

Liu Dan also cautioned that the design and control of precisely programmable drugs would be highly complex, necessitating a composite system. This complexity would be significantly greater in terms of mechanism and validation (e.g., degradation rates), and their applicability across different diseases would require personalized design. Given the novelty and challenges of this drug development approach, Chinese enterprises have not yet proactively pursued strategic investments in this area.

N1 Life CEO Zang Xiaoyu“It is believed that companies incubated by Flagship have consistently served as industry benchmarks, with a significant proportion focusing on drug delivery. Although information is currently limited, an overview of the company’s website reveals that its technological direction has transcended the level of protein receptor targeting. Instead, it places greater emphasis on distinguishing between healthy and diseased tissues, characterizing different tissue features through multi-omics to ensure precise drug delivery to the intended tissues. This represents an emerging trend. The AND-Body technology also places particular emphasis on the pharmaceutical developability of novel therapeutics; therefore, it can be anticipated that this will evolve into a multi-layered, controllable delivery platform integrating both biological and chemical technologies.”

“The core challenge that all delivery systems must overcome is achieving selective drug action at the target site, with the key lying in practical implementation. The unified and systematic breakthroughs currently demonstrated by the company are highly compelling; close attention should be paid to how its technical details are realized in the future.”Wang Haotian, Vice President of Investments at Legend Capital“Tell Artery New Medicine, ‘In short, we are very curious about this platform technology and full of expectations.’”

In a striking coincidence, on the very day Ampersand lifted the veil of mystery surrounding its operations, Rapport Therapeutics, another newly founded company also headquartered in Boston, made its public debut with $100 million in Series A financing.

Rapport was co-founded by venture capital firm Third Rock Ventures and Johnson & Johnson’s investment arm, JJDC, building on the research of molecular neuroscientist Dr. David Bredt. Dr. Bredt previously led neuroscience research at Eli Lilly and Johnson & Johnson, and currently serves as Chief Scientist at Rapport.

Bredt discovered the receptor-associated protein (RAP) and its role in regulating receptor expression. Rapport’s platform leverages genomics, proteomics, and brain imaging technologies to identify RAPs for precision neurotherapeutics. Unlike current treatments for neurological disorders, Rapport’s approach focuses on targeting receptors in the specific neuroanatomical regions responsible for the disease. To date, Rapport has only one clinical pipeline: a product for treating drug-resistant epilepsy, which is currently in Phase I clinical trials.

Both Ampersand and Rapport aim to achieve greater precision than previous targeted therapies by combining specific molecular targets or mutations with treatments that are more closely aligned with disease-relevant tissues and cells.Industry insiders believe that this further represents the future direction of precision medicine.

Even in the United States, the programmable and modular drugs advocated by Flagship are highly advanced.

Flagship’s business model is to create new companies based on cutting-edge science. Flagship is often referred to as a venture capital firm, but this is a misconception. Flagship does not provide funding to external companies; instead, it conceives, builds, and launches its own companies.

Asking “What if?” is central to Flagship’s culture of innovation. In the biotechnology sector, Flagship conceives, creates, and launches so-called “biological platform companies,” each of which leverages new technological capabilities or technologies and applies them to the development of multiple drugs or biotechnologies. It can be said that every Flagship company has a “core biological platform” capable of generating numerous potential therapeutic candidates and addressing a wide range of disease areas.

Kahvejian spent 12 years at Flagship Pioneering, primarily leading a team in the invention and launch of novel therapeutic platforms. Companies he helped found include Ring Therapeutics, Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, and Cellarity.

However, platform-based biotech companies (especially those with longer development timelines) are facing stricter scrutiny from investors than in previous years. In this environment, Ampersand Biomedics has been in existence for two years and has grown to 33 employees.

Whether Ampersand’s key initiatives can realize Flagship’s ambitions, address industry pain points, and unlock new industrial opportunities remains to be seen.